Rechercher des projets européens

Plus de 40 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS (LIVERHOPE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies tha...
Voir le projet

 18

 TERMINÉ 

Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection (HIVACAR)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planne...
Voir le projet

 16

 TERMINÉ 

Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,

Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte...
Voir le projet

 44

 TERMINÉ 

REgenerative therapy of intervertebral disc: a double blind phase 2b trial of intradiscal injection of mesenchymal stromal cells in degenerative disc disease of the lomber SPINE unresponsive to conventional therapy (RESPINE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

The World Health Organisation (WHO) has included low back pain in its list of twelve priority diseases. Notably, Degenerative disc disease (DDD) presents a large, unmet medical need which results in a disabling loss of mechanical function. Today, no efficient therapy is available. Chronic cases often receive surgery, which may lead to biomechanical problems and accelerated degeneration of adjacent...
Voir le projet

 18

 TERMINÉ 

3-O-sulfated heparan sulfate translocation in altered membrane biology: A newstrategy for early population screening and halting Alzheimer’s neurodegeneration (ArrestAD)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,

ArrestAD proposes a novel and visionary thinking resulting from the demonstration of the central role of a particular heparan sulfate species at the intracellular level in neurons and in circulating cells in the molecular pathology of Alzheimer’s disease (AD). AD is a societal challenge for which there is neither prevention nor possible cure. Research in the field has long been refining classic co...
Voir le projet

 8

 TERMINÉ 

Applied Public-Private Research enabling OsteoArthritis Clinical Headway (APPROACH)

Date du début: 1 juin 2015, Date de fin: 30 nov. 2020,

The problem: finding the right patient for the right treatmentDespite a large and growing disease burden in osteoarthritis (OA), many pharmaceutical companies have de-emphasized or even abandoned OA drug development due to perceived hurdles. Crucial in this is the lack of appropriate outcome measures that can robustly identify patient benefit from a specific therapy. The lack of specific and sensi...
Voir le projet

 25

 TERMINÉ 

A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients (MERCURIC)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2020,

Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omi...
Voir le projet

 13

 TERMINÉ 

Development of DIALIVE, a novel Liver Dialysis Device for the treatment of patients with Acute on Chronic Liver Failure (ACLF) (ALIVER)

Date du début: 1 janv. 2017, Date de fin: 30 sept. 2020,

Liver disease incidence is increasing and about 170K patients die from liver failure each year in Europe. In liver failure, the accumulation of protein bound toxins and increased susceptibility to infection cause multiorgan failure and death. Liver transplantation is the only treatment known to prolong the life but is limited by availability of organs. A clinically efficacious ‘liver dialysis devi...
Voir le projet

 12

 TERMINÉ 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke...
Voir le projet

 29

 TERMINÉ 

Application of omics-based strategies for improved diagnosis and treatment of endocrine hypertension (ENSAT-HT)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2020,

Arterial hypertension affects up to 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Yet, even small increments in blood pressure are associated with increased cardiovascular risk, with 62% of cerebrovascular disease and 49% of ischemic hear...
Voir le projet

 13

 TERMINÉ 

Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,

Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p...
Voir le projet

 44

 TERMINÉ 

Imaging the Force of Cancer (FORCE)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Cancer is the second leading cause of mortality in EU member states with ~90% of all cancer deaths caused by metastatic spread. Despite its significance, measuring metastatic potential as well as potential indicators of therapy efficacy remain unmet clinical challenges. Recently, it has been demonstrated in vitro, that aggressive metastatic cells pull on their surroundings suggesting that metastat...
Voir le projet

 18

 TERMINÉ 

European Prevention of Alzheimer’s Dementia Consortium (EPAD)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,

Background:The secondary prevention of Alzheimer’s dementia (AD) is achievable if we can identify individuals at risk of disease progression defined by biomarker evidence of AD pathology and no or only minimal clinical symptoms and engage them in a standing adaptive clinical trial, of the highest quality, testing multiple interventions. To achieve this, EPAD will also provide the analytical infras...
Voir le projet

 40

 TERMINÉ 

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease. (CARBALIVE)

Date du début: 1 mai 2015, Date de fin: 31 oct. 2019,

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins an...
Voir le projet

 15

 TERMINÉ 

A EUropean study on effectiveness and sustainability of current Cardiac Rehabilitation programmes in the Elderly (EU-CaRE)

Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,

Cardiovascular diseases (CVD) cause over 4 million deaths in Europe each year and mass disability: within the coming decades the disability-adjusted life years (DALYs) estimate is expected to rise from a loss of 85 million DALYs in 1990 to a loss of 150 million DALYs globally in 2020. Moreover, patient numbers are expected to rise rapidly in the next decades, due to an ageing society such that th...
Voir le projet

 11

 TERMINÉ 

Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2019,

ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro...
Voir le projet

 7

 TERMINÉ 

A drug strategy targeting stabilised mutant p53 to fight metastatic platinum-resistant ovarian cancer (GANNET53)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2019,

"Epithelial ovarian cancer (EOC) is the most lethal gyncaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations, and primary or acquired resistance to platinum-based chemotherapy profoundly contribute to the high mortality rate. With current standard therapy the median overall survi...
Voir le projet

 20

 TERMINÉ 

Decision Support and Information Management System for Breast Cancer (DESIREE)

Date du début: 1 févr. 2016, Date de fin: 31 janv. 2019,

Breast cancer is the most common type of cancer affecting woman in the EU. Multidisciplinary Breast Units (BUs) were introduced in order to deal efficiently with breast cancer cases, setting guideline-based quality procedures and a high standard of care. However, daily practice in the BUs is hampered by the complexity of the disease, the vast amount of patient and disease data available in the dig...
Voir le projet

 11

 TERMINÉ 

Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis (ADIPOA2)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Osteoarthritis (OA) is an incurable disease that has evaded pharmacological interference, biologic therapy or surgical intervention to prevent disease progression. Currently, OA is designated the 11th highest contributor (of 291 diseases) of global disability. In the absence of effective treatment options, cellular therapies using mesenchymal stem/stromal cells (MSCs) have emerged as potential can...
Voir le projet

 20

 TERMINÉ 

Metagenomics in Cardiometabolic Diseases (METACARDIS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2018,

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ag...
Voir le projet

 18

 TERMINÉ 

I-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly (I-MOVE-plus)

Date du début: 1 mai 2015, Date de fin: 31 oct. 2018,

The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share val...
Voir le projet

 33

 TERMINÉ 

European Clearing House for Open Robotics Development Plus Plus (ECHORD Plus Plus)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Description ECHORD++ will create new opportunities for European robotics researchers to work directly with SME/start-ups and new users/customers to create innovative products. ECHORD++ will continue ECHORD’s two pillars, “experiments” and “structured dialogue”, taking advantage of experience and investment in the infrastructure. In addition,...
Voir le projet

 68

 TERMINÉ 

Higher education student and staff mobility project

Date du début: 1 juin 2016, Date de fin: 31 mai 2018,

This is a higher education student and staff mobility project, please consult the website of the organisation to obtain additional details.
Voir le projet

 1

 TERMINÉ 

Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) (NET4CGD)

Date du début: 1 déc. 2012, Date de fin: 31 mai 2018,

This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD). This rare primary immune deficiency of phagocytes is caused by mutations in the gp91phox gene. Affected patients are highly-susceptible to infections and develop inflammatory granulomas. Several member...
Voir le projet

 11

 TERMINÉ 

Clinical Development of Nitisinone for Alkaptonuria (DEVELOPAKURE)

Date du début: 1 nov. 2012, Date de fin: 30 avr. 2018,

DevelopAKUre is a proposal to fund the clinical development of an orphan designated drug, nitisinone, for the treatment of a rare Mendelian disease, Alkaptonuria (AKU). AKU is a genetic deficiency of homogentisic acid dioxygenase, causing high levels of homogentisic acid (HGA). Oxidation of HGA to pigment polymer, termed ochronosis, alters connective tissues. This leads to multisystemic damage dom...
Voir le projet

 14

 TERMINÉ 

Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

Date du début: 1 mars 2013, Date de fin: 28 févr. 2018,

In renal allograft recipients, 10-year graft survival has not improved over the past decades. Histological examination of graft biopsies has long been the gold standard to confirm graft injuries, but biopsies are invasive and histological grading is not very robust. There is thus a need for robust, non-invasive methods to predict and diagnose acute and chronic graft lesions, to improve patient tre...
Voir le projet

 13

 TERMINÉ 

Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility (NanoAthero)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,

NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented...
Voir le projet

 17

 TERMINÉ 

Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT)

Date du début: 1 mars 2011, Date de fin: 31 déc. 2017,

RDEB is one of the most severe rare genetic skin diseases of children and adults characterized by skin blistering resulting from lack of expression of type VII collagen. There is no treatment for this life-threatening disease. In March 2009, we obtained the orphan drug designation for the Medicinal product: “Skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vecto...
Voir le projet

 10

 TERMINÉ 

Tissue engineering of the right heart outflow tract by a biofunctionalized bioresorbable polymeric valved tube (TEH-TUBE)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2017,

Approximately 42% of infants’ mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures which currently use inert materials without any growth potential. Consequently, multiple reoperations are often required, with their attendant high risk of mortality and m...
Voir le projet

 7

 TERMINÉ 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat...
Voir le projet

 28

 TERMINÉ 

Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased inciden...
Voir le projet

 13

 TERMINÉ 

European Medical Information Framework (EMIF)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim...
Voir le projet

 64

 TERMINÉ 

The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction (BAMI)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2017,

Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerativ...
Voir le projet

 23

 TERMINÉ 

EVA - patient ventilation beyond limits (EVA)

Date du début: 1 nov. 2015, Date de fin: 31 oct. 2017,

EVA - Expiratory Ventilation Assistance – , or expiration by suction, is an innovative method to mechanically ventilate patients and is a key step in ventilation towards less-invasive, tailored and improved patient care as it enables:1. full ventilation through a thin catheter instead of a thick tube2. low and – if needed – negative pressures in the lungs promoting blood circulation3. controlling ...
Voir le projet

 4

 TERMINÉ 

Prevention and Management of High Threat Pathogen Incidents in Transport Hubs (PANDHUB)

Date du début: 1 nov. 2014, Date de fin: 31 oct. 2017,

PANDHUB will create an integrated toolbox to aid transport operators and relevant actors in major transport hubs in the development of their current pandemic and dangerous pathogen preparedness and response plans. The project is intended to cover the extraordinary aspects specific to serious natural or man-made pathogen threats in the transport environment by providing accurate, reliable and valid...
Voir le projet

 9

 TERMINÉ 

European Consortium for High-Throughput Research in Rare Kidney Diseases (EURENOMICS)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts asse...
Voir le projet

 29

 TERMINÉ 

Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease (Repair-HD)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical ...
Voir le projet

 10

 TERMINÉ 

Semantics-driven Design through Geo and Building Information Modelling for Energy-efficient Buildings Integrated in Mixed-use Healthcare Districts (STREAMER)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

STREAMER is an industry-driven collaborative research project on Energy-efficient Buildings (EeB) with cases of mixed-use healthcare districts. Such districts are the best real examples of neighbourhood with integrated energy system consisting of mixed building types (i.e. hospitals and clinics; offices and retails; laboratories and educational buildings; temporary care homes, rehabilitation and s...
Voir le projet

 20

 TERMINÉ 

Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock (CULPRIT-SHOCK)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the i...
Voir le projet

 23

 TERMINÉ 

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS)

Date du début: 1 oct. 2013, Date de fin: 30 juin 2017,

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caus...
Voir le projet

 15